Moleculin Biotech, Inc. MBRX
We take great care to ensure that the data presented and summarized in this overview for Moleculin Biotech, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in MBRX
Top Purchases
Top Sells
About MBRX
Moleculin Biotech, Inc., a clinical-stage pharmaceutical company, focuses on the development of drug candidates for the treatment of highly resistant tumors and viruses. Its lead drug candidate is Annamycin that is in Phase 1/2 studies for the treatment of relapsed or refractory acute myeloid leukemia (AML) and cancers metastasized to the lungs. The company's flagship immune/transcription modulator is WP1066, which is in Phase I clinical trial for the treatment of brain tumors and pediatric brain tumors, as well as pancreatic cancer and other malignancies. It also develops WP1220, an analog of WP1066 for the topical treatment of cutaneous T-cell lymphoma; and WP1122 to treat glioblastoma multiforme and COVID-19. The company has partnership and collaboration agreements with MD Anderson; Animal Life Sciences, LLC; and WPD Pharmaceuticals Sp z.o.o. Moleculin Biotech, Inc. was incorporated in 2015 and is headquartered in Houston, Texas.
Insider Transactions at MBRX
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jul 02
2024
|
Walter V Klemp CEO and President |
SELL
Payment of exercise price or tax liability
|
Direct |
240
-0.42%
|
$720
$3.57 P/Share
|
|
Jul 02
2024
|
Walter V Klemp CEO and President |
BUY
Exercise of conversion of derivative security
|
Direct |
982
+1.69%
|
-
|
|
Jun 22
2024
|
Walter V Klemp CEO and President |
SELL
Payment of exercise price or tax liability
|
Direct |
2,190
-3.74%
|
$6,570
$3.74 P/Share
|
|
Jun 22
2024
|
Walter V Klemp CEO and President |
BUY
Exercise of conversion of derivative security
|
Direct |
8,990
+13.32%
|
-
|
|
Jun 22
2024
|
Jonathan P. Foster Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,053
-8.48%
|
$3,159
$3.74 P/Share
|
|
Jun 22
2024
|
Jonathan P. Foster Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
4,329
+25.85%
|
-
|
|
Jun 22
2024
|
Donald H Picker Chief Science Officer |
BUY
Payment of exercise price or tax liability
|
Direct |
524
+6.15%
|
$1,572
$3.74 P/Share
|
|
Jun 22
2024
|
Donald H Picker Chief Science Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,766
+17.16%
|
-
|
|
Jun 20
2024
|
Walter V Klemp CEO and President |
SELL
Payment of exercise price or tax liability
|
Direct |
914
-1.81%
|
$2,742
$3.78 P/Share
|
|
Jun 20
2024
|
Walter V Klemp CEO and President |
BUY
Exercise of conversion of derivative security
|
Direct |
3,750
+6.92%
|
-
|
|
Jun 20
2024
|
Jonathan P. Foster Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
636
-7.29%
|
$1,908
$3.78 P/Share
|
|
Jun 20
2024
|
Jonathan P. Foster Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,712
+23.72%
|
-
|
|
Jun 20
2024
|
Donald H Picker Chief Science Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
320
-4.52%
|
$960
$3.78 P/Share
|
|
Jun 20
2024
|
Donald H Picker Chief Science Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,078
+13.22%
|
-
|
|
Jun 16
2024
|
Walter V Klemp CEO and President |
SELL
Payment of exercise price or tax liability
|
Direct |
406
-0.86%
|
$1,624
$4.14 P/Share
|
|
Jun 16
2024
|
Walter V Klemp CEO and President |
BUY
Exercise of conversion of derivative security
|
Direct |
1,667
+3.42%
|
-
|
|
Jun 16
2024
|
Jonathan P. Foster Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
196
-3.16%
|
$784
$4.14 P/Share
|
|
Jun 16
2024
|
Jonathan P. Foster Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
834
+11.84%
|
-
|
|
Dec 26
2023
|
Walter V Klemp CEO and President |
BUY
Open market or private purchase
|
Direct |
188,404
+21.67%
|
$0
$0.69 P/Share
|
|
Dec 26
2023
|
Robert E. George Director |
BUY
Open market or private purchase
|
Direct |
14,493
+49.71%
|
$0
$0.69 P/Share
|
Last 12 Months Summary
| Exercise of conversion of derivative security | 26.1K shares |
|---|---|
| Open market or private purchase | 232K shares |
| Payment of exercise price or tax liability | 524 shares |
| Payment of exercise price or tax liability | 5.96K shares |
|---|